The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents

Breast Cancer Research and Treatment

Volumn 133, Issue 1, 2012, Pages 99-109

  Lu, Wenjie Jessie ^a   Xu, Cong ^a   Pei, Zifan ^b   Mayhoub, Abdelrahman S ^c   Cushman, Mark ^c   Flockhart, David A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Aromatase inhibitor; Breast cancer; Endoxifen; Estrogen; Norendoxifen; Tamoxifen

Indexed keywords

4' HYDROXYTAMOXIFEN; 4,4' DIHYDROXYTAMOXIFEN; AROMATASE; AROMATASE INHIBITOR; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; ENDOXIFEN; LETROZOLE; N DESMETHYL 4' HYDROXYTAMOXIFEN; N DESMETHYLDROLOXIFENE; NORENDOXIFEN; NORTAMOXIFEN; TAMOXIFEN DERIVATIVE; TAMOXIFEN N OXIDE; UNCLASSIFIED DRUG;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME INHIBITION; IC 50; MICROSOME; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; AROMATASE; AROMATASE INHIBITORS; BINDING SITES; BREAST NEOPLASMS; CATALYTIC DOMAIN; COMPUTER SIMULATION; DRUG DISCOVERY; FEMALE; HUMANS; ISOENZYMES; KINETICS; MICROSOMES; MODELS, MOLECULAR; NITRILES; TAMOXIFEN; TESTOSTERONE; THERMODYNAMICS; TRIAZOLES;

EID: 84860321539     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1699-4     Document Type: Article

References (44)

1. HJ Burstein AA Prestrud J Seidenfeld H Anderson TA Buchholz NE Davidson KE Gelmon SH Giordano CA Hudis J Malin EP Mamounas D Rowden AJ Solky MR Sowers V Stearns EP Winer MR Somerfield JJ Griggs 2010 American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer J Clin Oncol 28 23 3784 3796 10.1200/JCO.2009.26.3756 20625130 10.1200/JCO.2009.26.3756
2. CK Osborne H Zhao SA Fuqua 2000 Selective estrogen receptor modulators: structure, function, and clinical use J Clin Oncol 18 17 3172 3186 10963646 1:CAS:528:DC%2BD3cXntVCgsbY%3D
3. BJ Furr VC Jordan 1984 The pharmacology and clinical uses of tamoxifen Pharmacol Ther 25 2 127 205 0163-7258(84)90043-3 6438654 10.1016/0163-7258(84) 90043-3 1:CAS:528:DyaL2MXhs12nug%3D%3D (Pubitemid 14015738)
4. Y Jin Z Desta V Stearns B Ward H Ho KH Lee T Skaar AM Storniolo L Li A Araba R Blanchard A Nguyen L Ullmer J Hayden S Lemler RM Weinshilboum JM Rae DF Hayes DA Flockhart 2005 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 1 30 39 10.1093/jnci/dji005 15632378 10.1093/jnci/dji005 1:CAS:528: DC%2BD2MXisVaqsw%3D%3D
5. Lu WJ, Desta Z, Flockhart DA (2011) Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res Treat. doi: 10.1007/s10549-011-1428-z
6. B Fisher JP Costantino DL Wickerham RS Cecchini WM Cronin A Robidoux TB Bevers MT Kavanah JN Atkins RG Margolese CD Runowicz JM James LG Ford N Wolmark 2005 Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study J Natl Cancer Inst 97 22 1652 1662 10.1093/jnci/dji372 16288118 10.1093/jnci/dji372 1:CAS:528:DC%2BD2MXht1entb7L (Pubitemid 41672231)
7. JE Mortimer SW Flatt BA Parker EB Gold L Wasserman L Natarajan JP Pierce 2008 Tamoxifen, hot flashes and recurrence in breast cancer Breast Cancer Res Treat 108 3 421 426 10.1007/s10549-007-9612-x 17541741 10.1007/s10549-007-9612-x 1:CAS:528:DC%2BD1cXjsFGisbw%3D (Pubitemid 351431079)
8. NL Henry JM Rae L Li F Azzouz TC Skaar Z Desta MJ Sikora S Philips AT Nguyen AM Storniolo DF Hayes DA Flockhart V Stearns 2009 Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort Breast Cancer Res Treat 117 3 571 575 10.1007/s10549-009-0309-1 19153830 10.1007/s10549-009-0309-1
9. A Howell J Cuzick M Baum A Buzdar M Dowsett JF Forbes G Hoctin-Boes J Houghton GY Locker JS Tobias 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 9453 60 62 10.1016/S0140-6736(04)17666-6 15639680 10.1016/S0140-6736(04)17666-6 1:STN:280:DC%2BD2M%2FhsVartA%3D%3D (Pubitemid 40082147)
10. Zivian MT, Salgado B (2008) Side effects revisited: women's experiences with aromatase inhibitors. A report from Breast Cancer Action, San Francisco
11. MP Goetz JM Rae VJ Suman SL Safgren MM Ames DW Visscher C Reynolds FJ Couch WL Lingle DA Flockhart Z Desta EA Perez JN Ingle 2005 Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 36 9312 9318 10.1200/JCO.2005.03.3266 16361630 10.1200/JCO.2005.03.3266 1:CAS:528:DC%2BD28Xnt1ynuw%3D%3D
12. P Wegman S Elingarami J Carstensen O Stal B Nordenskjold S Wingren 2007 Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Res 9 1 R7 10.1186/bcr1640 17244352 10.1186/bcr1640 (Pubitemid 350215154)
13. SA Nowell J Ahn JM Rae JO Scheys A Trovato C Sweeney SL MacLeod FF Kadlubar CB Ambrosone 2005 Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 3 249 258 10.1007/s10549-004-7751-x 15952058 10.1007/s10549-004-7751-x 1:CAS:528:DC%2BD2MXltFGqsLs%3D (Pubitemid 40903087)
14. Z Desta BA Ward NV Soukhova DA Flockhart 2004 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6 J Pharmacol Exp Ther 310 3 1062 1075 10.1124/jpet.104.065607 15159443 10.1124/jpet.104.065607 1:CAS:528: DC%2BD2cXnt1eqtb0%3D (Pubitemid 39108928)
15. BS Katzenellenbogen I Choi R Delage-Mourroux TR Ediger PG Martini M Montano J Sun K Weis JA Katzenellenbogen 2000 Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology J Steroid Biochem Mol Biol 74 5 279 285 S0960-0760(00)00104-7 11162936 10.1016/S0960-0760(00)00104-7 1:CAS:528:DC%2BD3MXitFOqtw%3D%3D (Pubitemid 32126240)
16. YC Lim Z Desta DA Flockhart TC Skaar 2005 Endoxifen (4-hydroxy-N- desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen Cancer Chemother Pharmacol 55 5 471 478 10.1007/s00280-004-0926-7 15685451 10.1007/s00280-004-0926-7 1:CAS:528:DC%2BD2MXjtVWmtrk%3D (Pubitemid 40568978)
17. A Ahmad S Shahabuddin S Sheikh P Kale M Krishnappa RC Rane I Ahmad 2010 Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects Clin Pharmacol Ther 88 6 814 817 10.1038/clpt.2010.196 20981001 10.1038/clpt.2010.196 1:CAS:528:DC%2BC3cXhsVegu7bK
18. A Ahmad SM Ali MU Ahmad S Sheikh I Ahmad 2010 Orally administered endoxifen is a new therapeutic agent for breast cancer Breast Cancer Res Treat 122 2 579 584 10.1007/s10549-009-0704-7 20052538 10.1007/s10549-009-0704-7 1:CAS:528:DC%2BC3cXnsFymurY%3D
19. DL Hershman LH Kushi T Shao D Buono A Kershenbaum WY Tsai L Fehrenbacher S Lin Gomez S Miles AI Neugut 2010 Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients J Clin Oncol 28 27 4120 4128 10.1200/JCO.2009.25.9655 20585090 10.1200/JCO.2009.25.9655
20. V Ziller M Kalder US Albert W Holzhauer M Ziller U Wagner P Hadji 2009 Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer Ann Oncol 20 3 431 436 10.1093/annonc/mdn646 19150950 10.1093/annonc/mdn646 1:STN:280:DC%2BD1M7mvVynsA%3D%3D
21. AH Partridge A LaFountain E Mayer BS Taylor E Winer A Asnis-Alibozek 2008 Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer J Clin Oncol 26 4 556 562 10.1200/JCO.2007.11.5451 18180462 10.1200/JCO.2007.11.5451 1:CAS:528:DC%2BD1cXis1alsrc%3D (Pubitemid 351264348)
22. Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, Latif A, Hadfield KD, Clarke RB, Ashcroft L, Evans DG, Howell A, Nikoloff M, Lawrence J, Newman WG (2010) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat. doi: 10.1007/s10549-010- 1139-x
23. Y Muftuoglu G Mustata 2010 Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19) Bioorg Med Chem Lett 20 10 3050 3064 10.1016/j.bmcl.2010.03.113 20413308 10.1016/j.bmcl.2010.03.113 1:CAS:528:DC%2BC3cXlsFGnsrk%3D
24. B Sun J Hoshino K Jermihov L Marler JM Pezzuto AD Mesecar M Cushman 2010 Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer Bioorg Med Chem 18 14 5352 5366 10.1016/j.bmc.2010.05.042 20558073 10.1016/j.bmc.2010.05.042 1:CAS:528:DC%2BC3cXoslansrg%3D
25. S Yahiaoui C Pouget J Buxeraud AJ Chulia C Fagnere 2011 Lead optimization of 4-imidazolylflavans: new promising aromatase inhibitors Eur J Med Chem 46 6 2541 2545 10.1016/j.ejmech.2011.03.043 21497425 10.1016/j.ejmech.2011.03.043 1:CAS:528:DC%2BC3MXlsVCnurY%3D
26. HP Ciolino Z Dai V Nair 2011 Retinol inhibits aromatase activity and expression in vitro J Nutr Biochem 22 6 522 526 10.1016/j.jnutbio.2010.04.004 20685100 10.1016/j.jnutbio.2010.04.004 1:CAS:528:DC%2BC3MXmtFGjt70%3D
27. S Chen SR Oh S Phung G Hur JJ Ye SL Kwok GE Shrode M Belury LS Adams D Williams 2006 Anti-aromatase activity of phytochemicals in white button mushrooms (Agaricus bisporus) Cancer Res 66 24 12026 12034 10.1158/0008-5472. CAN-06-2206 17178902 10.1158/0008-5472.CAN-06-2206 1:CAS:528:DC%2BD28Xhtlagu7bJ (Pubitemid 46094217)
28. HP Ciolino TT Wang N Sathyamoorthy 2000 Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide Br J Cancer 83 3 333 337 10.1054/bjoc.2000.1269 10917548 10.1054/bjoc.2000.1269 1:CAS:528:DC%2BD3cXlslens78%3D (Pubitemid 30453573)
29. LS Adams Y Zhang NP Seeram D Heber S Chen 2010 Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro Cancer Prev Res (Phila) 3 1 108 113 10.1158/1940-6207.CAPR-08-0225 10.1158/1940-6207.CAPR-08-0225 1:CAS:528:DC%2BC3cXptFOjurc%3D
30. BJ Grube ET Eng YC Kao A Kwon S Chen 2001 White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation J Nutr 131 12 3288 3293 11739882 1:CAS:528:DC%2BD3MXpt1Gjuro%3D (Pubitemid 33136151)
31. WJ Lu R Bies LK Kamden Z Desta DA Flockhart 2010 Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase) Drug Metab Dispos 38 8 1308 1313 10.1124/dmd.110.032474 20410453 10.1124/dmd.110.032474 1:CAS:528: DC%2BC3cXhtVWktrjP
32. Lu WJ, Ferlito V, Xu C, Flockhart DA, Caccamese S (2011) Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms. Chirality
33. Stresser DM (2004) High-throughput screening of human cytochrome P450 inhibitors using fluorometric substrates. In: Yan Z, Caldwell GW (eds) Optimization in drug discovery: in vitro methods. Methods in pharmacology and toxicology, pp 215-230. doi: 10.1385/1-59259-800-5:215
34. S Jeong MM Woo DA Flockhart Z Desta 2009 Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro Cancer Chemother Pharmacol 64 5 867 875 10.1007/s00280-009-0935-7 19198839 10.1007/s00280-009-0935-7 1:CAS:528:DC%2BD1MXhtVSitLzP
35. D Ghosh J Griswold M Erman W Pangborn 2009 Structural basis for androgen specificity and oestrogen synthesis in human aromatase Nature 457 7226 219 223 10.1038/nature07614 19129847 10.1038/nature07614 1:CAS:528: DC%2BD1MXitlSitA%3D%3D
36. ML Verdonk JC Cole MJ Hartshorn CW Murray RD Taylor 2003 Improved protein-ligand docking using GOLD Proteins 52 4 609 623 10.1002/prot.10465 12910460 10.1002/prot.10465 1:CAS:528:DC%2BD3sXmvFGrsLg%3D (Pubitemid 37034158)
37. A Oberguggenberger M Hubalek M Sztankay V Meraner B Beer H Oberacher J Giesinger G Kemmler D Egle EM Gamper B Sperner-Unterweger B Holzner 2011 Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs) Breast Cancer Res Treat 128 2 553 561 10.1007/s10549-011-1378-5 21311968 10.1007/s10549-011-1378-5 1:CAS:528:DC%2BC3MXnslehtr0%3D
38. NL Henry JT Giles V Stearns 2008 Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management Oncology 22 12 1401 1408 19086600
39. EA Lien K Wester PE Lonning E Solheim PM Ueland 1991 Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients Br J Cancer 63 4 641 645 2021551 10.1038/bjc.1991.147 1:STN:280:DyaK3M3hsVygtg%3D%3D
40. MD Johnson H Zuo KH Lee JP Trebley JM Rae RV Weatherman Z Desta DA Flockhart TC Skaar 2004 Pharmacological characterization of 4-hydroxy-N- desmethyl tamoxifen, a novel active metabolite of tamoxifen Breast Cancer Res Treat 85 2 151 159 10.1023/B:BREA.0000025406.31193.e8 15111773 10.1023/B:BREA.0000025406.31193.e8 1:CAS:528:DC%2BD2cXjsVertbc%3D (Pubitemid 38987269)
41. F Tian H Wu Z Li N Wang J Huang C Li F Xie 2009 Activated PKCalpha/ERK1/2 signaling inhibits tamoxifen-induced apoptosis in C6 cells Cancer Invest 27 7 802 808 10.1080/07357900802672720 19544110 10.1080/07357900802672720 1:CAS:528:DC%2BD1MXpt1Kitb0%3D
42. AB da Rocha DR Mans EA Bernard C Ruschel AF Logullo LA Wetmore A Leyva G Schwartsmann 1999 Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU Eur J Cancer 35 5 833 839 S0959804999000039 10505046 10.1016/S0959-8049(99)00003-9 1:CAS:528:DyaK1MXjvFyisrk%3D (Pubitemid 29258155)
43. A Punetha K Shanmugam D Sundar 2011 Insight into the enzyme-inhibitor interactions of the first experimentally determined human aromatase J Biomol Struct Dyn 28 5 759 771 21294587 1:CAS:528:DC%2BC3MXisFOjtbw%3D
44. VC Jordan 2007 New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer Steroids 72 13 829 842 10.1016/j.steroids.2007.07.009 17765940 10.1016/j.steroids.2007.07.009 1:CAS:528:DC%2BD2sXhtVOit77L (Pubitemid 47410069)